The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.0M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 695K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

34 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Inhibition of the Aldehyde Dehydrogenase 1/2 Family by Psoralen and Coumarin Derivatives.EBI
Indiana University School of Medicine
Exploring the Existing Drug Space for Novel pTyr Mimetic and SHP2 Inhibitors.EBI
Indiana University School of Medicine
Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.EBI
Indiana University School of Medicine
Therapeutic potential of targeting the oncogenic SHP2 phosphatase.EBI
Indiana University School of Medicine
Development of selective inhibitors for aldehyde dehydrogenases based on substituted indole-2,3-diones.EBI
Indiana University School of Medicine
Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells.EBI
Indiana University School of Medicine
A potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases.EBI
Indiana University School of Medicine
[11C]olanzapine, radiosynthesis and lipophilicity of a new potential PET 5-HT2 and D2 receptor radioligand.EBI
Indiana University School of Medicine
Discovery and evaluation of novel inhibitors of mycobacterium protein tyrosine phosphatase B from the 6-Hydroxy-benzofuran-5-carboxylic acid scaffold.EBI
Indiana University School of Medicine
Structural analysis of bengamide derivatives as inhibitors of methionine aminopeptidases.EBI
Indiana University School of Medicine
Identification and characterization of novel inhibitors of mPTPB, an essential virulent phosphatase from Mycobacterium tuberculosis.EBI
Indiana University School of Medicine
Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases.EBI
Indiana University School of Medicine
Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis.EBI
Indiana University School of Medicine
Synthesis and in vitro biological evaluation of carbon-11-labeled quinoline derivatives as new candidate PET radioligands for cannabinoid CB2 receptor imaging.EBI
Indiana University School of Medicine
Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).EBI
Indiana University School of Medicine
Therapeutic Activity of the Lansoprazole Metabolite 5-Hydroxy Lansoprazole Sulfide in Triple-Negative Breast Cancer by Inhibiting the Enoyl Reductase of Fatty Acid Synthase.EBI
Indiana University School of Medicine
Exploiting the HSP60/10 chaperonin system as a chemotherapeutic target for colorectal cancer.EBI
Indiana University School of Medicine
Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents.EBI
Indiana University School of Medicine
Design and Synthesis of Fragment Derivatives with a Unique Inhibition Mechanism of the uPARĀ·uPA Interaction.EBI
Indiana University School of Medicine
Analogs of nitrofuran antibiotics are potent GroEL/ES inhibitor pro-drugs.EBI
Indiana University School of Medicine
Discovery and Development of Small-Molecule Inhibitors of Glycogen Synthase.EBI
Indiana University School of Medicine
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.EBI
Indiana University School of Medicine
Dual-targeting GroEL/ES chaperonin and protein tyrosine phosphatase B (PtpB) inhibitors: A polypharmacology strategy for treating Mycobacterium tuberculosis infections.EBI
Indiana University School of Medicine
Synthesis and in vitro biological evaluation of new P2X7R radioligands [EBI
Indiana University School of Medicine
Diversity-Oriented Synthesis for Novel, Selective and Drug-like Inhibitors for a Phosphatase from Mycobacterium Tuberculosis.EBI
Indiana University School of Medicine
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.EBI
Indiana University School of Medicine
Hydroxybiphenylamide GroEL/ES Inhibitors Are Potent Antibacterials against Planktonic and Biofilm Forms of Staphylococcus aureus.EBI
Indiana University School of Medicine
Structure-Based Optimization of a Novel Class of Aldehyde Dehydrogenase 1A (ALDH1A) Subfamily-Selective Inhibitors as Potential Adjuncts to Ovarian Cancer Chemotherapy.EBI
Indiana University School of Medicine
Sulfonamido-2-arylbenzoxazole GroEL/ES Inhibitors as Potent Antibacterials against Methicillin-Resistant Staphylococcus aureus (MRSA).EBI
Indiana University School of Medicine
Small molecules inhibit STAT3 activation, autophagy, and cancer cell anchorage-independent growth.EBI
Indiana University School of Medicine
Discovery of a Small Molecule Probe That Post-Translationally Stabilizes the Survival Motor Neuron Protein for the Treatment of Spinal Muscular Atrophy.EBI
Indiana University School of Medicine
Design and Structure-Guided Development of Novel Inhibitors of the Xeroderma Pigmentosum Group A (XPA) Protein-DNA Interaction.EBI
Indiana University School of Medicine
Screening and X-ray crystal structure-based optimization of autotaxin (ENPP2) inhibitors, using a newly developed fluorescence probe.BDB
The University of Tokyo